{"entity":{"id":"nct06462794","kind":"trial","name":"First In Human Study of CX-801 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of CX-801 run by CytomX Therapeutics, now recruiting.","summary":"First In Human Study of CX-801 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT06462794 by CytomX Therapeutics, with 121 participants planned, started 2024-08-28. Conditions recorded: Solid Tumor, Adult. Interventions recorded: CX-801 and pembrolizumab.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06462794","url":"https://clinicaltrials.gov/study/NCT06462794"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cx-801"],"companies":["cytomx-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06462794","phase":"1","setting":"An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors","sponsor":"CytomX Therapeutics","enrolled":121,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06462794/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"cx-801","kind":"drug","name":"CX-801","route":"/drugs/cx-801/"}],"company":[{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/"}]}}